Inspire Medical Systems (STU:2DR) ROCE %: -0.55% (As of Mar. 2026)

What is Inspire Medical Systems ROCE %?

Inspire Medical Systems STU:2DR +1.59% 55 ROCE % is -0.55% as of Mar. 2026. GuruFocus rates STU:2DR with a GF Score™ of 55/100 and a GF Value™ of €192.49 (Possible Value Trap). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Inspire Medical Systems's annualized ROCE % for the quarter that ended in Mar. 2026 was -0.55%.

Inspire Medical Systems (STU:2DR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Inspire Medical Systems ROCE % Related Terms

Inspire Medical Systems ROCE % Historical Data

* Premium members only.

The historical data trend for Inspire Medical Systems's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inspire Medical Systems ROCE % Chart

Inspire Medical Systems Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-16.08

-11.49

-3.56

9.03

8.15

Inspire Medical Systems Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-0.84	-1.31	7.65	26.79	-0.55

55GF Score

Inspire Medical Systems Inc STU:2DR

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Inspire Medical Systems ROCE % Calculation

Inspire Medical Systems's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	56.222	/	( ( (772.006 - 84.518)	+	(774.849 - 82.031) )	/ 2 )
	=	56.222	/	( (687.488	+	692.818)	/ 2 )
	=	56.222	/	690.153
	=	8.15 %

Inspire Medical Systems's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-3.868	/	( ( (774.849 - 82.031)	+	(788.34 - 77.347) )	/ 2 )
	=	-3.868	/	( ( 692.818	+	710.993 )	/ 2 )
	=	-3.868	/	701.9055
	=	-0.55 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -0.55% mean?

Inspire Medical Systems (STU:2DR) has a ROCE % of -0.55% as of Mar. 2026.

Is Inspire Medical Systems' ROCE % too high?

Inspire Medical Systems' current ROCE % is -0.55%. Overall, Inspire Medical Systems has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Inspire Medical Systems' ROCE % compare to BFLY and ATEC?

Inspire Medical Systems' ROCE % of -0.55% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inspire Medical Systems's current ROCE % is -0.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Inspire Medical Systems stock overvalued right now?

Based on GuruFocus' analysis, Inspire Medical Systems (STU:2DR) is currently considered Possible Value Trap. The stock's GF Value™ is €192.49, compared to a current price of €38.40 — trading 80.1% below its estimated fair value. The current ROCE % is -0.55%. Inspire Medical Systems' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Inspire Medical Systems (STU:2DR), the current ROCE % is -0.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inspire Medical Systems (STU:2DR) Overvalued in 2026?

Based on GuruFocus' analysis, Inspire Medical Systems stock appears to be undervalued. The current stock price of €38.40 is trading 80.1% below its estimated GF Value™ of €192.49. GuruFocus considers Inspire Medical Systems to be Possible Value Trap.

Key valuation signals for STU:2DR:

ROCE %: -0.55%
GF Value™: €192.49 vs. price of €38.40 (80.1% below fair value)
GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the STU:2DR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Inspire Medical Systems Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies BFLY ATEC TNDM IRMD AVNS IART ENOV AORT CNMD AHCO ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Other Exchanges INSP:USA

Address 5500 Wayzata Boulevard, Suite 1600, Golden Valley, MN, USA, 55416

Website https://www.inspiresleep.com

Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.

55GF Score

Get the complete analysis for STU:2DR

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€38.40

Price

€192.49

GF Value

View STU:2DR Analysis

See ROCE % data for all stocks →